Prevention of venous thromboembolism after major orthopedic surgery: Update and contribution of a specific synthetic inhibitor of factor Xa;Prévention de la maladie thrombo-embolique veineuse après chirurgie orthopédique majeure: État des lieux et place d'un inhibiteur synthétique et spécifique du facteur Xa

Revue de Chirurgie Orthopedique et Reparatrice de l'Appareil Moteur

Volumn 89, Issue 8, 2003, Pages 712-724

  Samama, M M ^a  

^a HÔTEL DIEU   (France)

Author keywords

Enoxaparine; Factor Xa inhibitor; Pentasaccharide; Sodium fondaparinux; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 9A INHIBITOR; BLOOD CLOTTING INHIBITOR; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PENTASACCHARIDE; POLYSACCHARIDE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; DRUG MECHANISM; FEMUR NECK FRACTURE; HUMAN; KNEE SURGERY; LUNG EMBOLISM; MAJOR SURGERY; META ANALYSIS; ORTHOPEDIC SURGERY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS; FACTOR XA; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0347993766     PISSN: 00351040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. GEERTS WH, HEIT JA, CLAGETT GP, PINEO GF, COLWELL CW, ANDERSON FA JR et al.: Sixth ACCP Consensus Conference on antithrombotic therapy. Prevention of venous thromboembolism. Chest, 2001, 119 (Suppl), 132S-175S.
2. NICOLAIDES AN: Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance withe the scientific evidence. Int Angiol, 2001, 20, 1-37.
3. HEIT JA: The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med, 2002, 162, 1806-1808.
4. ROSENCHER N, BARRÉ J, OSMAN M, SAMAMA M: Prévention thrombo-embolique en chirurgie orthopédique prothétique du membre inférieur. Maîtrise orthopédique, 2002, 117, 24-28.
5. EIKELBOOM JW, QUINLAN DJ, DOUKETIS JD: Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet, 2001, 358, 9-15.
6. COHEN AT, BAILEY CS, ALIKHAN R, COOPER DJ: Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty - a meta-analysis. Thromb Haemost, 2001, 85, 940-941.
7. SARRET M, KHER A, TOULEMONDE F: Low molecular weight heparin therapy. An evaluation of clinical trials evidence. Ed. Marcel Dekker Inc., 1999.
8. SAMAMA MM, GEROTZIAFAS GT, HORELLOU MH: Prophylaxie de la maladie thrombo-embolique. Rev Prat, 2003, 53, 51-57.
9. SAMAMA MM, GEROTZIAFAS GT: Evaluation of the pharmalogical properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb Research, 2003, 109, 1-11.
10. WALENGA JM, JESKE WP, BARA L, SAMAMA MM, FAREED J: Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res, 1997, 86, 1-36.
11. LORMEAU JC, HERAULT JP: The effect of the synthetic pentasaccharide SR90107/Org31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost, 1995, 74, 1474-1477.
12. WALENGA JM, BARA L, PETITOU M, SAMAMA M, FAREED J, CHOAY J: The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole antifactor Xa activity. Thromb Res, 1988, 51, 23-33.
13. PETITOU M, HERBERT JM: Les anticoagulants de synthèse. Pour la Science, 2000, 274, 1-8.
14. BASSAND JP: Les pentasaccharides. La Lettre du Cardiologue, 2002, 351, 25-28.
15. BONEU B, NECCIARI J, CARIOU R, SIE P, GABAIC, AM, KIEFFER G: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost, 1995, 74, 1468-1473.
16. TURPIE AGG, GALLUS AS, HOEK JA, for the Pentasaccharide Investigators: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med, 2001, 344, 619-625.
17. ERIKSSON BI, BAUER KA, LASSEN MR, TURPIE AG, for the Steering Committee of the Pentasaccharide in hip-fracture surgery study: Fondaparinux compared with exoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med, 2001, 345, 1298-1304.
18. LASSEN MR, BAUER KA, ERIKSSON BI, for the European Pentasaccharide Hip Elective Surgery Study Steering Committee : Postoperative fondaparinux versus preoperative enoxaparin for prevention on venous thromboembolism in elective hip-replacement surgery. A randomised double-blind comparison. Lancet, 2002, 359, 1715-1720.
19. BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AG, for the Steering Committee of the Pentasaccharide in major knee surgery study: Fondaparinux compared withe enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med, 2001, 345, 1305-1310.
20. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR, for the PENTATHLON 2000 Study Steering Committee: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hipreplacement surgery: a randomised double-blind comparison. Lancet, 2002, 359, 1721-1726.
21. ROSENCHER N, KERKKAMP HEM, MACHERAS G, MUNUERA LM, MENICHELLA G, BARTON DM et al.: Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion, 2003, 43, 459-469.
22. RASKOB GE, KEARON C, GEERTS W et al., for the bleeding complication study group: Bleeding complications of the thromboprophylaxis after hip replacement: a systematic review. ASH 2002, Session Thrombosis Haemosstatis, poster n° 1969.
23. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR et al., for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies: Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of four randomized double-blind studies. Arch Intern Med, 2002, 162, 1833-1840.
24. rd annual meeting and exposition, december 7-11, 2001: poster n° 224.
25. ERIKSSON BI, LASSEN MR, for the PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Investigators: Duration of prophylaxis against venous thromboembolism with fondaparinuw after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med, 2003, 163, 1337-1342.